HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.48T +44.4%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	36.10
Forward PE	16.40
Dividend	350.00 (0.64%)
Ex-Dividend Date	Mar 30, 2026

Volume	136,766
Average Volume	143,887
Open	54,400
Previous Close	54,300
Day's Range	52,300 - 54,600
52-Week Range	39,350 - 58,600
Beta	0.66
RSI	53.13
Earnings Date	Apr 28, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.